List view / Grid view

News

Coulter Partners appoints Finance Director, James Bichener FCCA to global team

13 May 2016 | By Coulter Partners

Global Life Sciences search specialist, Coulter Partners is pleased to announce the appointment of James Bichener as Finance Director. James brings a wealth of financial expertise gained both within executive search and beyond to augment the strategic strengths of the senior management team. “We are extremely fortunate to attract such…

Bayer terminates its Phase II riociguat PH-IIP trial

13 May 2016 | By Victoria White, Digital Content Producer

Reviewing data from the study, the DMC observed that patients receiving riociguat were at a possible increased risk for death and other serious adverse events...

NICE says ‘no’ to Opdivo for non-squamous NSCLC

12 May 2016 | By Victoria White, Digital Content Producer

In draft guidance, NICE has said ‘no’ to Opdivo for the treatment of patients with non-squamous NSCLC whose disease has progressed after prior chemotherapy...

Lilly’s psoriasis drug Taltz to generate sales over $1 billion by 2022

11 May 2016 | By Victoria White, Digital Content Producer

Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.